1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

AbbVie Assumes Two Interchangeable Humira Biosimilars In 2023

Up To Nine Adalimumab Biosimilars to Launch In Key Year

 
• By Dean Rudge

Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.

Billion_Dollar
Humira was a $15bn opportunity in the US in 2019 • Source: Shutterstock

Two biosimilar Humira (adalimumab) products that are set to enter the US market upon formation in 2023 will hold controversial interchangeability designations, according to originator AbbVie’s latest modelling assumptions for the world’s best-selling drug.

None of the 28 biosimilars approved by the US Food and Drug Administration to date, including several referencing Humira, has an official designation of interchangeability, despite the concept being established in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.